ODI Pharma receives approval from the Office for Registration of Medicinal Products in Poland
ODI Pharma AB (“ODI” or the “Company”) announces today that the Company has received approval from the Office for Registration of...
top of page
News
Please find below news from ODI Pharma AB. More stock relevant news can be found in the section "Stock Information" on the "INVESTORS" site.
Suche
ODI Pharma
- 25. Feb. 2022
- 4 Min.
Correction: ODI Pharma AB: Publication of half-year report 2021
Correction: ODI Pharma hereby discloses a revised half-year report for the period July – December 2021. In the previous report, the cost...
ODI Pharma
- 24. Feb. 2022
- 4 Min.
ODI Pharma AB: Publication of half-year report 2021
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2021. The report is available...
ODI Pharma
- 9. Juli 2021
- 2 Min.
ODI Pharma AB: Flagging notification
ODI Pharma AB (“ODI Pharma”) has been informed that Mr. Niclas Kappelin has acquired 20’000 shares in ODI Pharma and exceeded the...
ODI Pharma
- 21. Apr. 2021
- 3 Min.
ODI Pharma: Update on progress in “Project Poland” and “Project Skin”
In January 2021 and February 2021, ODI Pharma AB (“ODI” or the “Company”) announced the decision to expand its current business with...
ODI Pharma
- 22. Feb. 2021
- 2 Min.
ODI Pharma achieves milestone towards market entry in Poland
ODI Pharma AB (“ODI” or the “Company”) announces that its subsidiary ODI Pharma Polska Sp. z o.o. has finalized documentation and filed...
ODI Pharma
- 14. Jan. 2021
- 2 Min.
ODI Pharma proceeds with its plans and launches Project Skin
ODI Pharma AB (“ODI” or “the Company”) announces that the Board of Directors has decided to expand ODI’s current business with...
ODI Pharma
- 2. Nov. 2020
- 6 Min.
ODI PHARMA AB AND APHRIA INC. EXECUTE SUPPLY AGREEMENT
Stockholm, Sweden and Leamington, Ontario – November 2nd, 2020 – ODI Pharma AB (“ODI”, ISIN SE0013409760) today announced that, despite...
ODI Pharma
- 27. Aug. 2020
- 3 Min.
ODI Pharma AB: Publication of year-end report
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its year-end report for the period July 2019 – June 2020. The report is available...
ODI Pharma
- 7. Apr. 2020
- 2 Min.
ODI Pharma AB: Status update in connection to COVID-19
ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Board of Directors does not see any impact on the Company’s mid- and...
ODI Pharma
- 27. Feb. 2020
- 3 Min.
ODI Pharma AB: Publication of half-yearly report 2019
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its half-yearly report for the period October – December 2019. The report is...
ODI Pharma
- 20. Jan. 2020
- 2 Min.
First registration of ODI Pharma’s new share issue completed
Stockholm, 20.01.2020. ODI Pharma AB's ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed...
ODI Pharma
- 3. Jan. 2020
- 3 Min.
ODI Pharma’s new share issue prior to listing significantly oversubscribed
The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was...
ODI Pharma
- 16. Dez. 2019
- 4 Min.
ODI Pharma has been approved for listing on Spotlight Stock Market, subscription period starts today
ODI Pharma AB (“ODI Pharma” or “the Company”), a medical cannabis finished product producer, today announces that the Company has been...
bottom of page